Focus Partners Advisor Solutions LLC Has $3.34 Million Holdings in Bristol Myers Squibb Company $BMY

Focus Partners Advisor Solutions LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 129.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,437 shares of the biopharmaceutical company’s stock after purchasing an additional 40,340 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Bristol Myers Squibb were worth $3,338,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Norges Bank acquired a new position in Bristol Myers Squibb during the second quarter worth $1,554,154,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after buying an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock worth $523,599,000 after acquiring an additional 9,171,098 shares in the last quarter. Man Group plc lifted its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Bristol Myers Squibb by 142.8% during the 2nd quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company’s stock valued at $390,541,000 after purchasing an additional 4,961,869 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.8%

NYSE BMY opened at $62.32 on Thursday. The business’s fifty day moving average is $57.42 and its 200-day moving average is $50.84. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock has a market capitalization of $126.91 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BMY. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Leerink Partners upped their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Finally, Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average price target of $60.71.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.